» Articles » PMID: 11406768

A Simplified System for Constructing Recombinant Adenoviral Vectors Containing Heterologous Peptides in the HI Loop of Their Fiber Knob

Overview
Journal Gene Ther
Date 2001 Jun 15
PMID 11406768
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

The use of recombinant adenovirus (Ad) vectors containing genetically modified capsid proteins is an attractive strategy for achieving targeted gene transfer. The HI loop of the fiber knob is a promising candidate location for the incorporation of foreign ligands for achieving this goal. However, the method of constructing an Ad vector containing a foreign ligand in the HI loop of the fiber knob has proved difficult. In this study, we developed a simple system to construct fiber-modified vectors. To do this, a vector plasmid containing a complete E1/E3-deleted Ad type 5 genome and a unique Csp45I and/or ClaI site between positions 32679 and 32680 of the Ad genome (residues threonine-546 and proline-547 of the fiber protein) was constructed. Oligonucleotides corresponding to the Arg-Gly-Asp (RGD) or Asn-Gly-Arg (NGR)-containing peptide motif (as a model) and containing a Csp45I and/or ClaI recognition site, were ligated into the Csp45I and/or ClaI-digested plasmid. The foreign transgene expression cassette was inserted into the E1 deletion site of the vector plasmid and the fiber-mutant Ad vector was produced by transfection of the PacI-digested plasmid into 293 cells. The virus containing the RGD or NGR peptide on the fiber knob was able to infect human glioma cells, which do not express coxsackievirus and adenovirus receptor (CAR), one of the Ad virus receptors, about 100-1000 times more efficient than the virus containing wild-type fiber. This suggested that the mutant virus mediated CAR-independent cell entry pathway. The simplicity of this method allows not only for easy construction of fiber-mutant Ad vectors, but also for screening of the peptides that target the vector to the desired cells and tissues.

Citing Articles

Use of patient-derived organotypic tumor spheroids for testing of viral vector gene therapy in combination with checkpoint blockade.

Domingues A, de Oliveira S, Tessarollo N, Lepique A, Rodrigues O, Sharova T Mol Ther Oncol. 2025; 33(1):200942.

PMID: 40034966 PMC: 11874566. DOI: 10.1016/j.omton.2025.200942.


Utilizing Adenovirus Knob Proteins as Carriers in Cancer Gene Therapy Amidst the Presence of Anti-Knob Antibodies.

Koizumi N, Hirai T, Kano J, Sato A, Suzuki Y, Sasaki A Int J Mol Sci. 2024; 25(19).

PMID: 39409008 PMC: 11476472. DOI: 10.3390/ijms251910679.


Effects of pre-existing anti-adenovirus antibodies on transgene expression levels and therapeutic efficacies of arming oncolytic adenovirus.

Ono R, Nishimae F, Wakida T, Sakurai F, Mizuguchi H Sci Rep. 2022; 12(1):21560.

PMID: 36513733 PMC: 9747716. DOI: 10.1038/s41598-022-26030-3.


Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation.

Cerqueira O, Clavijo-Salomon M, Cardoso E, Tortelli Junior T, Mendonca S, Barbuto J Front Immunol. 2020; 11:576658.

PMID: 33193370 PMC: 7642851. DOI: 10.3389/fimmu.2020.576658.


Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector.

David T, Cerqueira O, Lana M, Medrano R, Hunger A, Strauss B Sci Rep. 2020; 10(1):17893.

PMID: 33087767 PMC: 7578831. DOI: 10.1038/s41598-020-74826-y.